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in any medium, provided the original work is properly citeDeregulated proliferation is a hallmark of cancer cells. Here, we show that
microRNA-10b is a master regulator of breast cancer cell proliferation and is
downregulated in tumoural samples versus matched peritumoural counterparts.
Two canonical CpG islands (5 kb) upstream from the precursor sequence are
hypermethylated in the analysed breast cancer tissues. Ectopic delivery of
synthetic microRNA-10b in breast cancer cell lines or into xenograft mouse
breast tumours inhibits cell proliferation and impairs tumour growth in vivo,
respectively. We identified and validated in vitro and in vivo three novel target
mRNAs of miR-10b (BUB1, PLK1 and CCNA2), which play a remarkable role in cell
cycle regulation and whose high expression in breast cancer patients is associ-
ated with reduced disease-free survival, relapse-free survival andmetastasis-free
survival when compared to patients with low expression. This also suggests that
restoration of microRNA-10b expression might have therapeutic promise.INTRODUCTION
MicroRNAs (miRs) are evolutionarily conserved, small non-
coding RNA molecules that negatively regulate gene expression
at the post-transcriptional level, binding through partialnal Cancer Institute,
izmann Institute of
a National Cancer
ncer Institute, Rome,
stitute, Rome, Italy
. Vincenzo Hospital,
, USA
McMaster University
Institute of Science,
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C BY 3.0), which permits u
d.sequence homology to the 30-untranslated region (30-UTR) of
target mRNAs and causing translational inhibition and/or
mRNA degradation (Bartel, 2004). Several studies have indeed
demonstrated that miRs are highly specific for tissue and
developmental stages. Computational analyses indicate that
each miR can regulate hundreds of genes, thus influencing
critical cellular processes such as differentiation, cell growth,
stress response and cell death (Miska, 2005; Zamore & Haley,
2005). Recent studies have demonstrated that aberrant
expression of miRNA genes can be associated with different
pathologies including cancers (Calin & Croce, 2006; Croce,
2009), suggesting that miRs have a potential role as oncogenes
or tumour suppressor genes (Cimmino et al, 2005; Johnson et al,
2005; Voorhoeve et al, 2006).
Deciphering the molecular mechanisms involved in breast
tumourigenesis has been the subject of extensive research in last
years; yet unpredictable response and development of resis-
tance to adjuvant therapies remain major challenges in the
management of breast cancer patients. The power of miR
expression signatures has emerged recently from several
studies. Normal and breast tumour tissues can be discriminated
by a miR signature as reported by Iorio et al (Iorio et al, 2005)
and recent findings have also linked deregulatedmiR expression
to breast cancer metastasis (Huang et al, 2008; Martello et al,is an open access article under
se, distribution and reproduction
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Francesca Biagioni et al.2010; Tavazoie et al, 2008). In addition to being potential
diagnostic markers, miRs were also associated with clinical and
pathological features and outcome in different tumour types
(Calin et al, 2005; Iorio et al, 2008; Shell et al, 2007; Takamizawa
et al, 2004; Yanaihara et al, 2006). These results suggest that
alteredmiR expressionmay be important for the pathogenesis of
breast cancer.
In our study, we measured miR expression profiles from
56 matched tumour and peritumoural breast cancer tissues as
well as from 5 tumour and 3 peritumour unmatched samples.
Our aim was to identify new miRs involved in the process of
neoplastic transformation.
The microarray data analysis identified, in every subgroup of
breast cancers analysed, a specific subset of miRs that were
differentially expressed in tumour compared to peritumoural
tissues. We found that microRNA-10b was downregulated in
tumoural samples of all three types when compared to their
matched peritumoural counterparts. This is due to hypermethyl-
ation of CpG islands found upstream from the miR10b/10b
locus.
A miR can be derived from each arm of the pre-miR hairpin.
The less common of these two miR products is identified by
the  next to the miR name (Bhayani et al, 2012). The more
widely characterized miR derived from this precursor is
miR-10b. Overexpression of miR-10b in non-metastatic breast
tumours leads to tumour invasion and distant metastasis in
xenotransplantation models (Ma et al, 2007). Conversely,
silencing of miR-10b expression suppresses metastasis in a
mouse mammary tumour model (Ma et al, 2010). On the
other hand, very little is known about the role of miR-10b in
breast transformation. We found that miR-10b controls cell
cycle progression and proliferation by targeting the expression
of BUB1, PLK1 and CCNA2, and that low expression levels of
these three genes are, to various extents, predictive of less
aggressive disease and of longer relapse- and metastasis-free
survival. Finally, we showed that intratumoural delivery of
miR-10b impaired breast xenograft tumour growth. This is
accompanied by reduced expression of BUB1, PLK1 and CCNA2
proteins and proliferation markers.RESULTS
Deregulation of miR expression between tumoural and
peritumoural breast cancer tissues
In exploring the potential involvement of miRs in breast
tumourigenesis, we profiled the miR expression of 64 primary
breast cancer patients, comprising 56 matched tumour and
adjacent peritumoural breast tissues as well as 5 tumour and
3 peritumour unmatched tissues, using the Agilent micro-
array platform. The pathological characteristics of the
samples collection are summarized in Supporting Information
Table S1.
Several statistical analyses were combined (including noise
estimation, t-test and comparison of matched sample pairs,
see Materials and Methods section) in order to identify a subset
of miRs significantly differentially expressed between tumourEMBO Mol Med (2012) 4, 1214–1229 and peritumour samples, done separately for each of the three
breast cancer subgroups studied (Fig 1A–C). We identified 22
differentially expressed miRs in HER2-overexpressing (HER2þ)
tumours, 31 in Basal-like tumours and 33 in Luminal tumours
(Supporting Information Tables S2 and S3A–S3C). Among these
miRs, we identified two (miR-10b and miR-139-5p) that were
down-regulated and three (miR-425, miR-454 and miR-301a)
that were up-regulated for all three subtypes (Fig 1D and E and
Supporting Information Fig S1A). To evaluate the reliability of
our results, we first validated by RT-qPCR the up- and down-
regulation of these five-shared miRs in a small group of samples
derived from the same patient cohort (Supporting Information
Fig S1B). Next, we validated our results by RT-qPCR in an
independent set of HER2þ and Basal-like tumour samples and
their matched peritumoural tissues (Fig 1F and Supporting
Information Table S4). Thus, up-regulation of miR-425, miR-454
andmiR-301a and down-regulation of miR-10b andmiR-139-5p
were definitively confirmed.
These results indicate that specific modifications in the
miR expression pattern are characteristic of human breast
cancer tissue when compared to their matched peritumoural
samples. Furthermore, there is a group of miRs that is similarly
deregulated in all three major subgroups of breast cancer.
CpG island hypermethylation contributes to microRNA-10b
down-regulation in breast cancer samples
Downregulation of miRs has generally been observed in various
types of human cancer, including breast cancer. This might
suggest that some of these miRs act as tumour suppressor genes
(TSGs; Kumar et al, 2007; Lu et al, 2005; Ozen et al, 2008). Since
the down-regulation of many TSGs in human cancer has been
frequently linked to the hypermethylation of CpG sites located
within their promoter regions, the samemechanismmay play an
important role in silencing tumour suppressor miRs in tumours.
To investigate whether the down-regulation of miR-10b and
miR-139-5p could be attributable to hypermethylation events
occurring during breast carcinogenesis, we first examined the
genomic loci of miR-10b and miR-139-5p for the presence of
CpG islands (Supporting Information Fig S2A and S2B). Given
that miR-10b is an intergenic miR, we analysed a 5Kb-long
region upstream from the miR-10b precursor coding sequence
using the UCSC Genome Browser. We found two CpG islands
located 2659 bp and 82 bp upstream the precursor sequence,
respectively (Fig 2A). miR-139-5p is an intragenic miR located in
the PDE2A gene and consequently the 5 kb upstream PDE2A
transcription start site and the entire gene sequence were
evaluated. We analysed one intragenic CpG island located at
27,116 bp upstream from the miR genomic precursor sequence.
To evaluate whether these CpG islands undergo methylation,
the genomic DNA extracted from MCF7 cells was immunopre-
cipitated with an antibody directed to 5-methylcytosine (5mC).
As shown in Fig 2B, both CpG islands upstream of miR-10b
were found to be methylated. Very low levels of methylation
were observed on the CpG island upstream of miR-139-5p
(Fig 2B). This could suggest that other epigenetic mechanisms
might underlie its down-regulation in breast tumours. Of note,
methylation of miR10b/10b CpG islands was abrogated when2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1215
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Figure 1. Expression profiles of the miRs, which differentiate breast tumour from matched peritumour samples.
A–C. SPIN-ordered (see Materials and Methods section) expression matrix of the miRs differentially expressed between HER2þ (panel a, 22 miRs), Basal-like
(panel b, 31 miRs) and Luminal (panel c, 33 miRs) breast tumours and their matched peritumour samples. Colours indicate expression levels after centering
and normalizing each miR (row), with red denoting relatively high expression and blue relatively low expression.
D. Venn diagram showing the numbers of shared and not shared differentiating miRs between the various subtypes of breast cancer. miRs that are up (down)
regulated in the tumour tissue are shown on the left (right).
E. Box-plots of the expression levels (log base 2 scale) of the five shared miRs in tumour (T) and peritumour (PT) samples in each breast cancer subtype.
F. RT-qPCR analysis of the five-shared miRs in matched tumour (T) and peritumour (PT) samples of HER2þ and Basal-like subtypes in a second cohort of
32 representative patients (16 HER2þ and 16 Basal-like patients).
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Figure 2. miR-10b locus is hypermethylated in breast cancer.
A. Schematic representation of the miR-10b and miR-139-5p genomic loci. The analysed CpG islands are indicated (solid lines).
B. MeDIP analysis on breast cancer cell lines was performed as described in the text. Immunoprecipitated genomic DNA from MCF7 cell line was quantified by
using qPCR with TaqMan assays directed to miR-10b CpG islands #1 and #2 and miR-139-5p CpG Island #1.
C. MeDIP experiment of MCF7 cells treated with 5-aza-dC. The percentage of enrichment over the INPUT of both CpG island #1 and #2 diminishes in the cells
treated with the demethylating agent. NT¼not treated cells.
D,E. RT-qPCR analysis of pri-miR-10b (D), mature miR-10b and miR-10b (E) expression was performed in MCF7 breast cancer cells treated with the
demethylating agent 5-aza-dC versus untreated cells (NT).
F. Bisulphite sequencing results from four matched tumoural and peritumoural breast patient samples. Results were averaged for each CpG position, whereby
the number of investigated clones is presented between parenthesis and the shading of each circle represents the percentage of methylation as indicated.
Relative positions of nucleotides inside the CpG islands are indicated.
G MeDIP experiments performed on genomic DNA extracted from breast cancer tissues. MeDIP were carried out with antibody directed against
5-methylcitidine in two breast cancer and two reductive mammoplasty samples. N¼ reductive mammoplasty. The immunoprecipitated genomic DNA was
quantified by qPCR using TaqMan assays amplifying miR-10b CpG Island #1, CpG Island #2 and miR-139-5p CpG Island #1. Relative enrichments are
presented as percentages of the input DNA used for the immunoprecipitations.
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12185-Aza-20-deoxycytidine (5-aza-dC), a demethylating agent, was
added to the MCF7 cell culture (Fig 2C). There was almost no
effect of the treatment on the analysed miR-139 CpG island
(Fig 2C). The expression analyses demonstrated that the
microRNA-10b precursor (Fig 2D), as well as the mature
miR-10b and -10b (Fig 2E), are induced in MCF7 cells following
5-aza-dC pharmacological treatment. This finding is in line with
the methylation status of CpG islands upstream of miR-10b.
5-aza-dC treatment did not affect the expression of the three up-
regulated miRs (miR-425, miR-454 and miR-301a; Supporting
Information Fig S2C). To provide further evidence to the role of
CpG island methylation to the down-regulation of miR-10b
expression, we investigated the methylation status of the two
CpG islands mentioned above using genomic DNA derived from
six matched tumour and peritumoural breast tissues. Bisulphite
conversion followed by sequencing revealed that CpG island
#2 displays a significant (p¼ 0.035) higher overall degree of
methylation (69.6%) in four tumour specimens, when com-
pared to their matched peritumour samples (31.6%; Fig 2F).
As shown in Fig 2G, MeDIP analysis demonstrated a higher
methylation degree of both CpG islands located upstream to
miR-10b in the tumour samples in comparison to matched
peritumour samples. MeDIP analysis performed on genomic
DNA extracted from unmatched mammary healthy tissues of
two reductive mammoplasties exhibited very low levels of
methylation for both CpG#1 and GpG#2 islands (Fig 2G).
Altogether, these results indicate that methylation of CpG
islandsmay underlie down-regulation of miR-10b expression in
breast cancer samples.
miR-10b inhibits the proliferation of breast cancer cell lines
To elucidate the biological significance of the down-regulation
of miR-10b and miR-139-5p in breast cancer, we analysed
potential correlations between their expression and commonly
known clinical attributes. As shown in Fig 3A, a statistically
significant negative correlation was found between miR-10b
expression and tumour size (T). Lower levels of miR-10b
correspond to higher tumour sizes (Fig 3A). Since altered cell
proliferation correlates with tumour size, we investigated the
effects of miR-10b expression on cell proliferation.
Transduction of miR-10b mimic reduced the proliferation
capacity of MCF7 and MDA-MB-468 cells when compared to
the cells transduced with control mimic (Fig 3B and C). No
significant variation was found in cells over-expressing
miR-139-5p (Fig 3B and C). Accordingly, the percentage of
Ki67-positive cells in the miR-10b-over-expressing MCF7 and
MDA-MB-468 populations was substantially lower than in
control cells (Fig 3D). No differences were observed in the
miR-139-5p-over-expressing population (Fig 3D).
We next analysed the effect of miR-10b or miR-139-5p
expression on cell-cycle distribution by flow cytometry. In
MDA-MB-468 cells over-expressing miR-10b, there was a
significant decrease in G1 phase accompanied by an increase
in the subG1 phase of the cell cycle compared to control
cells (Fig 3E and F), indicating perturbation of cell cycle.
Indeed, TUNEL assay performed under the same experimental
conditions clearly confirmed an increase in the percentage of 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.apoptotic cells in the miR-10b-over-expressing population
compared to control cells (Fig 3G and Supporting Information
Fig S3A and S3B). In miR-10b-over-expressing MCF7 cells, we
observed a decrease in S phase accompanied by an increased
sub-G1 fraction of the cell cycle compared to control cells
(Fig 3H and I and Supporting Information Fig S3C). The
5-bromo-20-deoxyuridine (BrdU) incorporation assay confirmed
that miR-10b-over-expressing MCF7 cells are less proliferating
than control cells (Fig 3J and Supporting Information Fig S3D).
No significant effects of miR-139-5p expression on the cell cycle
were observed either in MDA-MB-468 or in MCF7 cells (Fig 3E
and H).
The ability of miR-10b expression to inhibit cell proliferation
was further confirmed by colony formation assays in MCF7 cells
(Fig 3K). Soft agar colony formation assays indicated that
miR-10b over-expression reduced the ability of cells to grow in
an anchorage-independent manner (Fig 3L). Altogether, these
results show that miR-10b inhibits the proliferation of breast
cancer cell lines.
miR-10b represses cell cycle regulatory genes with
prognostic power in breast cancer
To unravel the molecular mechanisms through which miR-10b
exerts its tumour suppressor functions and is involved in the
regulation of cell cycle and proliferation, we first searched for
putative miR-10b target mRNAs. Of the available sequence-
based miR target prediction algorithms, Microcosm Targets
(http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/)
is the only one that provides targets of miR-10b. We identified
736 putative target genes and since many of these are likely
to be false positives, we used a publicly available dataset
(Enerly et al, 2011) that contains expression data for both
miR-10b and mRNA from 100 breast cancer patients to
provide a filter for putative targets. Specifically, we calculated
the correlation between the expression levels of these 736
putative target genes and those of miR-10b. Forty-two of the
predicted target genes ofmiR-10bwere significantly (10%FDR)
anti-correlatedwith themiR’s expression levels, andwe selected
these as our candidate targets. Using the DAVID tool (Dennis
et al, 2003; Huang da et al, 2009), we searched for pathways
enriched for these candidate targets. The cell cycle pathway was
significantly enriched, much more than any other pathway,
encompassing seven out of the predicted 42 genes (correspond-
ing to <0.001% FDR; Supporting Information Table S5A and
S5B). We investigated the expression levels of the seven
putative target genes contained in the cell cycle pathway: the
three targets among these seven genes with the most negatively
correlated expression to the miR were CCNA2, PLK1, and BUB1
(p< 0.0005, see Fig 4A and Supporting Information Fig S4A).
These three genes were selected and subjected to detailed
experimental investigations.
BUB1 is a serine/threonine protein kinase bound to
kinetochores and plays a key role in the establishment of
mitotic spindle checkpoint and chromosome congression
(Elowe, 2011). PLK1 controls G2/M transition supporting the
centrosomes’ maturation in late G2/early prophase and bipolar
spindle formation (de Carcer et al, 2011). CCNA2 belongs to theEMBO Mol Med (2012) 4, 1214–1229
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3
1220highly conserved cyclin family, whose members are character-
ized by protein abundance oscillation, and controls cell cycle
in G1/S and G2/M transitions (Malumbres & Barbacid,
2009). The BUB1-, PLK1- and CCNA2-encode mRNA contains
30-UTR elements that are partially complementary to miR-10b
(Supporting Information Fig S4B). To formally demonstrate that
miR-10b targets BUB1, PLK1 and CCNA2mRNAs, the 30-UTR of
each of the three targets was cloned down-stream to the Renilla
luciferase gene into the psiCHEK2 vector (Supporting Informa-
tion Fig S4C). As shown in Fig 4B, miR10b co-transfection
significantly decreased the Renilla luciferase activity of the
vector encoding the BUB1 30-UTR. This was also observed using
the PLK1 30-UTR (Fig 4C) and the CCNA2 30-UTR (Fig 4D). A
partial recovery of the luciferase activity was observed when
vectors carrying targets 30-UTR of BUB1, PLK1 and CCNA2,
with mutations in the miR-10b complementary sequences,
were tested (Fig 4B–D).
To examine the effect of miR-10b expression on the protein
levels of these targets, MCF7, MDA-MB-468 and SKBR3 cells
(which have a lower level of miR-10b expression compared
with MCF10A cells, see Supporting Information Fig S4D) were
transfected with miR-10b mimic or control mimic and the
protein levels of BUB1, PLK1 and CCNA2 were analysed by
Western blot. As shown in Fig 4E–G, miR-10b exogenous
expression strongly reduced the amount of BUB1, PLK1 and
CCNA2 protein in all cell lines. Conversely, the transfection of
an inhibitor ofmiR-10b activity in untransformedMCF10A cells
leads to an increase of BUB1, PLK1 and CCNA2 protein levels
(Fig 4H–J and Supporting Information Fig S4E and S4F).
Analysis of these miR-10b targets by immunohistochemistry
(IHC) in ten matched breast tumour and peritumoural tissues
(from the cohort analysed by microarray miR profiling) showed
remarkable increased staining of BUB1, PLK1 and CCNA2 in the
tumour tissues (Fig 4K).
To further investigate the involvement of miR-10b in control
of proliferation through the modulation of these cell cycle
regulatory proteins, we tested three different siRNA molecules
for BUB1, PLK1 or CCNA2 in MCF7 cells. The knock-down of
each miR-10b target in each experimental condition testedFigure 3. miR-10b expression affects breast cancer cells proliferation. All the
experiments SE. The statistical significance was determined by Student’s t test
A. Box-plots of the expression levels of miR-10b and miR-139-5p for tumours
size was calculated by Spearman correlations (correlation-coefficient value
B,C. Growth curves of MDA-MB-468 (B) and MCF7 (C) cells transfected with miR
performed harvesting the cells after 24, 48 and 72 h from transfection.
D. Ki67 proliferation marker was evaluated by immunocytochemistry in MDA-M
(MIM 139-5p) or control mimic (CTRL). The upper panel shows representat
E–G. Cell cycle analysis of MDA-MB-468 cells transfected with MIM 10b or MIM 1
phase are expressed as a percentage of the total cell number. p< 0.05. (F) Th
control mimic is shown. (G) The percentage of positive cells in TUNEL assay o
H–J. Cell cycle analysis on MCF7 cells transfected with the indicatedmimic molecu
as a percentage of the total cell number. p< 0.05. (I) The ratio of S values of
(J) MCF7 cells overexpressing MIM 10b or control mimic were treated with B
K. Colony formation assay was performed in MCF-7 cells transfected with the i
the cells after 21 days with crystal violet.
L. Soft agar assay was performed in MCF7 cells transfected with mimic ctrl o
 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.caused a significant reduction (albeit to different extents) in the
colony-forming ability of MCF7 cells (Supporting Information
Fig S4G–S4L). We also subcutaneously inoculated immuno-
deficient SCID mice with MDA-MB-468 cells, whose expression
of BUB1, PLK1 or CCNA2 proteins was concomitantly knocked-
down. Before the inoculation, the transduced cells were tested
for the efficiency of the silencing of BUB1, PLK1 and CCNA2 as
shown in Fig 4L. Inoculated mice were sacrificed 3 weeks after
cell inoculation and, as shown in Fig 4M and N, cells whose
expression of BUB1, PLK1 and CCNA2 was concomitantly
silenced engrafted less efficiently than those transfected with
control siRNA.
When the prognostic value of BUB1, PLK1 and CCNA2
expression was evaluated using publicly available breast cancer
microarray datasets (with associated clinical information), we
found that high expression levels of all three genes are predictive
of lower disease-free survival in the datasets from Ivshina et al.
(Ivshina et al, 2006) and Miller et al. (Miller et al, 2005; Fig 5A).
A statistically significant prognostic power of BUB1 was found
also in the dataset from Loi et al. (Loi et al, 2007) for both
relapse-free (Fig 5B) andmetastasis-free survival (Fig 5C), while
in the same dataset the CCNA2 expression was associated
only with onset of metastasis. A trend of association between
low miR-10b expression level and worse prognosis was also
evidenced by Kaplan–Meier analysis of the Enerly et al dataset
(Enerly et al, 2011; Supporting Information Fig S5).
Intra-tumoural delivery of miR-10b reduces tumour size in a
breast cancer xenograft model
To explore the therapeutic potential of miR-10b in established
tumours, we subcutaneously inoculated immunodeficient
SCID mice with human MDA-MB-468 breast cancer cells.
Three weeks after injection, when tumour cells had formed
solid and palpable tumours with an average volume of
100mm3, animals were subdivided into two groups and either
treated with miR-10b mimic or a negative control miR. The
inoculations were performed administering miR-10b mimic
by four intra-tumoural injections each every 3 days. The
synthetic miRs were complexed with siPORTamine (siPORT),histograms of the figure represent the mean of three independent
.
of different sizes (pT1< pT2<pT3). The correlation of expression with tumour
s (cc) and p-values (p) are indicated in each panel).
-10b (MIM 10b) or miR-139-5p (MIM 139-5p) or control mimic (CTRL) were
B-468 and MCF7 cells transfected with miR-10b (MIM 10b) or miR-139-5p
ive pictures while the graph shows the percentages of Ki67-positive cells.
39-5p or control mimic. (E) The percentage of cells in subG1, G0/G1, S and G2-
e ratio of subG1 values of miR-10b andmiR-139-5p-transfected cells over the
f MDA-MB-468 cells transfected with the indicated mimic molecules is shown.
les. (H) The percentage of cells in subG1, G0/G1, S and G2-phase are expressed
miR-10b and miR-139-5p-transfected cells over the control mimic is shown.
rdU to analyse DNA synthesis. Quantification of (BrdU)-positive cells is shown.
ndicated mimic molecules by seeding 1103 cells in 60mm dishes and fixing
r mimic 10b by seeding 1 104 cells for 2 weeks.
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1222a lipid-based transfection reagent that enhances cellular
uptake of the oligonucleotide (Trang et al, 2010). All mice
were sacrificed 5 days after the last injection. miR-10b
abundance was investigated in a subset of representative
tumours, both miR-10b-treated and control (Fig 6A). As shown
in Fig 6B, local delivery of synthetic miR-10b induced a
specific inhibitory response and robustly interfered with tumour
growth. The distribution of tumour volumes among the groups
of miR-10b-treated and control mice at the time of the last
injection is shown in Fig 6C. IHC analysis for BUB1, PLK1 and
CCNA2 proteins revealed a significant decrease of protein
level in mice injected with synthetic miR-10b compared to
control mice [Fig 6D and E (I–III)]. Ki-67 and Cyclin D1
protein expression was significantly (Ki67 p¼ 0.009; CCND1
p¼ 0.0008) decreased in their levels in the tumours injected
with miR-10b, compared to control tumours [Fig 6D and
E (IV–V)]. miR-10b-treated tumours also showed a significantly
higher number of TUNEL-positive cells than those injected with
control mimic (Supporting Information Fig S6).
Overall, in vivo observations on the effect of miR-10b
expression in breast cancer tumours together with those
observed in cell lines confirm the key role of miR-10b in the
control of breast cancer cell proliferation.DISCUSSION
In the present study, we identified miR-10b as a master
regulator of breast cancer cell proliferation. We showed that
down-regulation of miR-10b expression occurs specifically in
breast tumour specimens when compared to their matched
peritumoural samples. The analysed sample collection included
breast cancer specimens representative of Luminal, Triple-
Negative and HER2-amplified disease subtypes. miR-10b falls
among those miRs whose deregulated expression features in
all of the three breast cancer subtypes. This suggests that
down-regulation of miR-10b expression might precede those
oncogenic alterations, which contribute to breast cancerFigure 4. miR-10b down-regulates the expression of BUB1, PLK1 and CCNA2
A. SPIN-ordered expressionmatrix ofmiR-10b and its seven predicted target ge
expression levels after centering and normalizing each gene (row), with re
The colour bar at the bottom represents the breast tumour subtypes – pink f
for Normal-like and white for unknown subtype).
B–D. Expression vectors carrying a luciferase reporter followed by the 30-UTR regi
mutated in themiR-10b complementary sequence (grey bars), were transfec
luciferase activity values from three independent experiments in triplicate
E–G. Immunoblotting of BUB1 (E), PLK1 (F) and CCNA2 (G) in MDA-MB-468, SKB
H–J. Immunoblotting of BUB1 (H), PLK1 (I) and CCNA2 (J) in MCF10a cells trans
K. Immunohistochemical analysis of BUB1, PLK1 and CCNA2 protein expression
peritumour). Representative images of invasive ductal breast carcinomas (tum
more than 50% of tumour cells and their relative peritumour tissues are sh
immunostaining for BUB1 (upper graph) or PLK1 (middle graph) or CCNA2
L. Immunoblotting of BUB1, PLK1 and CCNA2 in MDA-MB-468 tumours deriv
M. Tumour volumes measured 3 weeks after the injection. The central bold line
n¼10 in 3xsiRNA group) and the circles data points. p-value was calculat
N. Immunohistochemistry quantification of Ki67 (V) expression from five repre
shown. p-values were calculated by two sample t-test, and indicated in th
 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.subtype specificity. Our findings, together with those published
by Weinberg’s group (Ma et al, 2007, 2010), highlight the
key roles of the miR-10b locus in breast cancer establishment
(miR-10b) and spreading (miR-10b). Indeed, miR-10b is
highly expressed in metastatic breast cancer as well as in
other advanced tumours such as pancreatic ductal carcinoma
(Bloomston et al, 2007; Preis et al, 2011) and glioblastoma
tumours (Ciafre et al, 2005), while we show here that miR-10b
is down-regulated through hypermethylation of its regulatory
regions in primary breast cancers. This might suggest that
down-regulation of miR-10b promotes aberrant breast cancer
cell proliferation, which is later paired with increasedmigration,
invasion and metastasis as a consequence of the transcriptional
activation of miR-10b (Fig 7).
The regulation of the expression of a majority of miRs has yet
to be explored. This gap in our knowledge is mainly due to the
uncertainty regarding location of regulatory regions where
epigenetic modifications occur and binding sites for specific
transcription factors reside. Interestingly, the miR-10b/10b
locus appears to undergo both epigenetic modifications and
transcriptional activation in breast tumours. Methylation of
miR-10b/10b promoter CpG islands has been recently shown in
gastric cancer specimens (Kim et al, 2011). Here, we found that
CpG islands of miR-10b/10b are highly methylated in some
tumour specimens when compared to their matched peritu-
moural samples (Fig 2). The expression of miR-10b/10b
is regained when breast cancer cell lines are treated with
demethylating agents (Fig 2). Growing evidence shows that
miRs exert pleiotropic activities by controlling the expression
of diverse target mRNAs. It has been shown that miR-10b
suppresses the synthesis of Hoxd10 protein increasing the
expression of the pro-metastatic gene products RhoC, urokinase
activator plasminogen receptor (uPAR), a3-integrin and MT1-
MMP (Ma et al, 2007; Sasayama et al, 2009; Sun et al, 2011).
Other validated mRNA targets of miR-10b include KLF4 in
human oesophageal cancer cell lines (Tian et al, 2010) and the
nuclear receptor co-repressor 2 (NCOR2) in neuroblastomas
(Foley et al, 2011). The computational analysis reveals thatproteins in breast cancer cell lines.
nes connected to cell cycle, across 100 breast cancer tumours. Colours indicate
d denoting relatively high expression and blue relatively low expression.
or HER2þ, purple for Basal-like, blue for Luminal A, Cyan for Luminal B, orange
ons of BUB1 (B), PLK1 (C) or CCNA2 (D), in their wild-type form (black bars) or
ted in H1299 cells in the presence ofmimic-10b or control mimic. Normalized
are shown. p< 0.01; p< 0.05.
R3 and MCF7 cells transfected with either mimic-10b or control mimic.
fected with either antagomiR-10b or antagomiR control.
was analysed in ten representative breast cancer tissues (matched tumour and
our) where BUB1 (I), PLK1 (II) and CCNA2 (III) show nuclear immunostaining in
own (scale bar 30mm). Right graphs depict the percentage of tissues showing
(lower graph) in the group of tumours or peritumours.
ed from triple siRNA (3xsiRNA) SCID mice.
s denote mean values, the vertical lines SEM (n¼9 mice in siGFP group and
ed by two-samples t-test and indicated in the figure.
sentative siGFP control and 3xsiRNA (siBUB1, siPLK1 and siCCNA2) mice are
e figure.
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Figure 5. Clinical association of miR-10b target gene expression with survival of breast cancer patients.
A–C. The association between expression levels of miR-10b target genes (BUB1, PLK1 and CCNA2) and disease (A)/relapse (B)/distant metastasis (C) – free
survival was evaluated by Kaplan–Meier analysis in three public datasets, Ivshina et al. (Ivshina et al, 2006), 249 patients, Miller et al. (Miller et al, 2005),
237 patients and Loi et al. (Loi et al, 2007), 135 patients. The two compared groups are the third of patients with the highest expression levels of each
target gene (red) versus the third of patients with the lowest expression (blue). Statistically significant results (p-value< 0.05) are indicated by the
presence of .putative target genes of miR-10b which are anti-correlated to
the miR expression levels, are involved in various cellular
pathways (Supporting Information Table S5A). Among those,
seven putative target mRNAs encode for proteins involved in
the control of cell cycle (Supporting Information Table S5B).
Here, we document that down-regulation of miR-10b correlates
with aberrant expression of PLK1, BUB1 and CCNA2 proteins inEMBO Mol Med (2012) 4, 1214–1229 breast cancer specimens when compared to their matched
peritumoural samples. Restoration of miR-10b expression by
using mimic 10b reduces PLK1, BUB1 and CCNA2 protein
expression in diverse breast cancer cell lines (Fig 4E–G). The
miR-10b antagomiR expression increases the protein levels of
PLK1, BUB1 and CCNA2 in MCF-10A cells (Fig 4H–J). siRNA-
mediated down-regulation of PLK1 or BUB1 or CCNA2 impairs2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1223
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3the ability of MCF-7 cells to form colonies (Supporting
Information Fig S4J–S4L). miR-10b targets the 30-UTR region
of BUB1, PLK1 and CCNA2 transcripts (Fig 4B–D). Interestingly,
the analysis of gene expression databases of different cohorts of
breast cancer patients reveals that those expressing high levels
of PLK1, BUB1 or CCNA2 exhibit lower disease-free survival
when compared to those expressing low levels (Fig 5A). High
expression of BUB1 correlates with shorter relapse-free survival
(Fig 5B). Patients with high expression of BUB1 and CCNA2
exhibit reduced metastasis-free survival when compared to
patients with low expression (Fig 5C).
It has been reported that miR-10b antagomir suppresses
breast cancer metastasis in vitro and in vivo without having any
effect on the primary breast tumours (Ma et al, 2010). Here, we
provide evidence that xenografted human breast tumours in
mice, when injected with synthetic miR-10b, show impaired
tumour growth characterized by a significantly reduced
proliferative index (Fig 6A–E).
Collectively, these findings have several implications:
(a) miR-10b down-regulation has a profound impact on breast
cancer proliferation by disabling proper cell cycle regulation;
(b) the expression of BUB1, PLK1 and CCNA2 proteins, whose
respective transcripts are targets of miR-10b, is dysregulated in
different human cancers. This may suggest that alteration of
miR-10b expression plays a role in establishing also other types
of tumours. Indeed, we found that down-regulation of miR-10b
occurs also in gastric and head and neck tumours when
compared to their matched peritumoural tissues (Unpublished
observation by FB, VC, AS, FG and GB); (c) the fine deciphering
of the molecular events governing the expression of themiR-10b
locus (miR-10b and miR-10b) may disclose novel therapeutic
targets to tackle breast tumourigenesis.MATERIALS AND METHODS
Cell viability and colony-formation assay
A half millilitre aliquot of cell suspension (obtained from MCF7 and
MDA_MB_468 cells transfected or not with miR-10b oligos), was
mixed with 0.5ml of 0.4% trypan blue dye and left for 5min at room
temperature. The cells were counted using the Thoma chamberigure 6. Intra-tumoural delivery of miR-10b reduces tumour size in a breast cancer xenograft model.
. Relative miR-10b abundance in MDA-MB-468 tumours. Total RNA was prepared from tumours harvested 5 day post the final treatment and RT–qPCR was
performed using probe specific for miR-10b. Ct values were used to calculate absolute miR-10b
 copy numbers and expressed relative to the average
expression in control tumours (1.0). Four representative mice for control group (numbered on x-axis #1, #2, #4 and #6) and miR-10b group (numbered on
x-axis #3, #4, #5 and #6) were shown.
. A total of 10106 MDA-MB-468 breast cancer cells in 30%matrigel were subcutaneously injected into immunodeficient SCID mice. On days 22, 24, 27 and
30 from cells inoculation, synthetic miR-10b or control double-stranded and ready-to-use miRs conjugated with the siPORT transfection reagent were
intratumourally delivered into groups of seven animals. Caliper measurements were taken to determine the length and width of each tumour and to
calculate total tumour volumes. Data is presented as mean SEM (n¼ 7 mice in each group). p-values were calculated by two-samples t-test; significant
results are marked by  (p-value for day 27¼0.0075 and p-value for day 30¼ 0.0045).
. Tumour volumes measured at day 30 after the first injection. The central bold lines denote mean values, the vertical lines SEM (n¼7 mice in each group)
and the circles data points. p-values was calculated by 2-samples t-test and indicated in the figure.
,E. Immunohistochemical analysis of BUB1, PLK1, CCNA2, CCND1 and ki67 protein expressionwas analysed in five representativemimic control andmimic 10b
treated mice. (D) Representative images and (E) relative quantification of BUB1 (I), PLK1 (II), CCNA2 (III), CCND1 (IV) and ki67 (V) positive cells of control and
miR-10b overexpressing tumours are shown.F
A
B
C
DEMBO Mol Med (2012) 4, 1214–1229 counting cells and the number of viable cells was determined. The
experiment was conducted in triplicate and every point was counted
4 times. With regard to colony-forming assays, 1103 cells were
seeded in 60-mm dishes and grown for 21 days. Cells were stained
with crystal violet and colonies counted.
Terminal deoxynucleotidyl transferase-mediated dUTP nick
end labelling assay
The DeadEnd Fluorimetric [terminal deoxynucleotidyl transferase-
mediated dUTP nick end labelling (TUNEL)] system from Promega
Corp. (Madison, WI) was used to detect apoptosis by fluorescence-
activated cell sorting analysis in the MDA-MB-468 cells following the
manufacturer’s protocol. Cellular fluorescence was measured using a
Guava EasyCyte 8HT flowcytometer.
Flow cytometry
Cells were harvested, washed with PBS and resuspended in 75%
ethanol in PBS and kept at 208C for at least 30min. Cells were
resuspended and incubated for 10min in a solution containing 0.1%
NP40 and 1mg/ml RNAse A in PBS. Propidium iodide (Sigma) at a final
concentration of 0.05mg/ml was then added. The suspension was
then analysed using a Guava EasyCyte 8HT flow cytometer. All flow
cytometry data were analysed using the FlowJo software (Tree Star,
Ashland, OR, USA).
Patients and samples
One hundred and twenty pairs of primary breast cancers were
obtained from patients from Italian National Cancer Institute ‘Regina
Elena’. Matched peritumour non-cancerous breast tissues were also
obtained from all the patients included in the study. The latter was
approved by the scientific ethic committee from Italian National
Cancer Institute ‘Regina Elena’ (protocol number 5E/459/10).
Informed consent was obtained from all subjects. All experiments
present in this work conformed to the principles set in the WMA
Declaration of Helsinki and the NIH Belmont Report.
For the purpose of our study, only histologically uninvolved breast
tissue sampled within 2 cm from tumour margin is defined as
peritumoural tissue. All tissue samples used throughout the study
were histologically examined before starting the experiments. Two
additional cases of reductive mammoplasty (normal samples derived
from individuals without cancer) were used as healthy control. The2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1225
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Figure 7. Schematic representation of working
model. miR-10b andmiR-10b are generated from a
common precursor. In primary breast tumours,
miR-10b is down-regulated by promoter
hypermethylation. This leads to upregulation of its
targets genes, BUB1, PLK1 and CCNA2 that are key
components of the cell cycle machinery. Such a
disregulation results in aberrant tumour cell
proliferation. In metastatic breast tumours, it has
been reported (Ma et al, 2007, 2010) that the
over-expression of miR-10b is strictly related to
the invasive program that leads to metastasis
formation.
1226cohort for microarray analysis consisted of 56 matched breast
tumour specimens, 5 unmatched tumour samples and 3 unmatched
peritumour samples. Following excision, tissue samples were
immediately frozen in liquid nitrogen and stored at 808 until RNA
extraction. The cohort of paraffin-embedded tissues used for array
validation consisted of 59 breast tumour specimens. Clinical and
pathological data relating to the clinical samples are shown in
Supporting Information Tables S1 and S4. ER, PRg and HER2/neu
status of the patients were determined by IHC on formalin fixed,
paraffin embedded sections of clinical specimens as part of routine
pathology to guide clinical decision regarding adjuvant therapy.
IHC was performed using rabbit monoclonal anti human ER
antibody (Dako, UK) and a polyclonal rabbit anti human PRg
antibody (Dako, UK). Membranous staining was scored for HER2/neu
(Dako, UK).
RNA extraction, labelling and microarray hybridization
Breast tumour tissue (50–100mg) was manually homogenized in 1ml
of TRI Reagent lysis reagent (Ambion) according to manufacturer’s
instructions. The concentration and purity of total RNA were assessed
using a NanodropTM 1000 spectrophotometer (Nanodrop Techno-
logies, Wilmington, DE, USA). Total RNA (100ng) was labelled and
hybridized to Human miRNA Microarray V2 (Agilent). Scanning and
image analysis were performed using the Agilent DNA Microarray
Scanner (P/N G2565BA) equipped with extended dynamic range (XDR)
software according to the Agilent miRNA Microarray System with
miRNA Complete Labeling and Hyb Kit Protocol manual. Feature
Extraction Software (Version 10.5) was used for data extraction from
raw microarray image files using the miRNA_105_Dec08 FE protocol.
miRNA expression data was deposited in Gene Expression Omnibus
(GEO) with accession number GSE40525. 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Microarray data analysis
Normalization
All arrays were normalized together using a Lowess multi-array
algorithm (Ballman et al, 2004), miRs that were not detected in all
samples according to GeneView flags were removed and all values
lower than 5 were considered below detection and thresholded to 5.
Noise estimation
Noise in the expression levels was estimated on the basis of
16 samples for which two replicates were measured. The noise did
not depend on the miR intensity levels and therefore was calculated
for all miRs together. Noise was estimated by the standard deviation
of the intensity differences between replicate samples.
Comparison of matched sample pairs (CMSP)
For each patient with both tumour and matched peritumour sample,
a p-value was calculated, for each miR, based on the difference of
expression of the miR between the two matched samples, divided by
the noise (standard deviation). The p-values for each specific miR from
all patients (from the same subtype) were combined together into
one p-value, using Fisher’s method (Mosteller & Fisher, 1948). Thus,
for each miR three p-values were calculated (one for each disease
subtype).
Identifying differentially expressed miRs between tumour and
peritumour samples in the various subtypes of breast cancer
Three statistical tests were used to define the group of differentially
expressed miRs in each subtype: (i) paired t-test (ii) 2-samples t-test and
(iii) CMSP (see above). For explanations and rationale for combining
the three tests see Supporting Information. After performing theseEMBO Mol Med (2012) 4, 1214–1229
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The paper explained
PROBLEM:
Breast cancer is still the leading cause of cancer death in women
worldwide. The aetiology of this type of cancer is complex and
both genetic and environmental factors contribute to its
complexity. Deciphering the molecular mechanisms involved in
breast tumourigenesis has been the subject of extensive research
in last years; yet unpredictable response and development of
resistance to adjuvant therapies remain major challenges in the
management of breast cancer patients.
RESULTS:
In the present study, we show that down-regulation of miR-10b
expression, through hypermethylation of its regulatory regions,
occurs specifically in breast tumour specimens when compared
to their matched peritumoural samples. We demonstrate that
miR-10b targets the expression of PLK1, BUB1 and CCNA2 cell
cycle regulatory proteins. Importantly, the aberrant expression of
these proteins exhibits prognostic value in breast cancer. We also
provide evidence that injection of synthetic miR-10b impaired
tumour growth of xenografted human breast tumours.
IMPACT:
Since miR-10b down-regulation is an alteration common to the
three major breast cancer subtypes, it might represent a critical
molecular event for breast cancer establishment. Thus,
restoration of miR-10b expression might hold therapeutic
potential for breast cancer treatment.three tests, a combined p-value is calculated for each miR in each
subtype, using Fisher’s method. To define the group of differentiating
miRs for each subtype, a version of the FDR procedure was used
(Zeisel et al, 2011). The level of significance used as threshold
was different for each subtype (Supporting Information Table S2),
since the number of patients in each subtype was different (and
we wanted to get differentiating lists of about the same sizes).
In addition to the threshold on the combined p-value, thresholds on
all three tests were also used since the combined p-value is very
sensitive to extremely low p-values and we wanted to eliminate miRs
which got extremely low p-value in one test only (see Supporting
Information Table S3A–S3C, for lists of differentiating miR in the
various subtypes and their p-values). Note that for the HER2R subtype
all patients had matched samples and therefore the two-samples
t-test was not used.
Sorting points into neighbourhood (SPIN)
SPIN is an unsupervised method for sorting and visualization of
multidimensional data (Tsafrir et al, 2005); it allows finding groups of
miRs that display similar expression patterns over a range of samples
(see Supporting Information).
Coupled miR and mRNA expression data
We used the publicly available dataset GSE19536 (Enerly et al, 2011)
from the Gene Expression Omnibus repository (Barrett & Edgar, 2006;
Edgar et al, 2002), which contains miR and mRNA expression data of
100 breast cancer tumours. We calculated the Pearson correlation and
corresponding p-values between expression levels of miR-10b and its
736 predicted target genes.
mRNA expression data
We used the publicly available data sets: GSE4922 (Ivshina et al,
2006), GSE3494 (Miller et al, 2005) and SE6532 (Loi et al, 2007). The
mRNA expression data was measured using Affymetrix Human
Genome U133A and B arrays and the preprocessing steps included
summarization by the Affymetrix Expression Console and normal-EMBO Mol Med (2012) 4, 1214–1229 ization of all arrays (from each data set) together, using our version of
Lowess multi-array algorithm (Ballman et al, 2004).
Kaplan–Meier analysis
The patients were divided into three equal groups based on the tested
mRNA expression levels (low, medium and high). The Kaplan–Meier
analysis (Clark et al, 2003) was performed between the highest and lowest
groups, to test for an association between the mRNA expression levels and
the survival of the patients. The medium group was excluded to ensure
difference in expression between the highest and lowest groups.
Methylated DNA immunoprecipitation assay (MeDIP)
DNA was isolated by incubating cells overnight at 378C in SDS/
proteinase K digestion buffer (NaCl 300mM, EDTA 25mM, Tris pH 8
50mM, SDS 2% e Prot K 0.2mg/ml). DNA was extracted twice with
phenol/chloroform followed by ethanol precipitation. Pellets were
resuspended in TE plus 20mg/ml RnaseA and the resulting DNA was
quantified on a Nanodrop spectrophotometer. Immunoprecipitation of
methylated DNA was prepared as (Weber et al, 2005); the antibody
against 5-methyl-cytosine used for immunoprecipitation was from
Abcam ab1884, San Diego, CA. Quantitative PCR (qPCR) reactions were
carried out in triplicate on specific genomic regions using TaqMan
Master Mix (Applied Biosystem). The list of probes (IDT) used for
amplification on methylated region was summarized in Supporting
Information Table S9. The resulting signals were normalized for primer
efficiency by carrying out qPCR for each primer pair using Input DNA.
Bisulphite sequencing
Genomic DNA was extract with Trizol protocol and purified with
Wizard genomic DNA purification kit (Promega, Madison, WI). A total
of 500 ng of genomic DNA was converted with Qiagen EpiTect
Bisulphite kit following the manufacturer’s instructions and amplified
by PCR with primer set designed using MethPrimer software (Li &
Dahiya, 2002). Primer sequences are presented in Supporting
Information Table S10. PCR product were isolated from 2% agarose
gels using Nucleospin extract II (Macherey Nagel). Subsequently, they2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1227
Research Article www.embomolmed.org
miR-10b* controls breast cancer cell proliferation
1228were ligated into pCR2.1 using TA cloning kiy (Invitrogen). Individual
clones were sequenced on Big Dye V3.1 Cycle-Sequencing kit (Applied
Biosystems) with M13 Fw and M13 Rw primers. Sequencing reactions
were analysed on to 3130 Genetic Analyzer (Applied Biosystems).
Multiple clones (20) were sequenced and average methylation levels
are represented. All clones had a C to T conversion at non-CpGs higher
that 99%.
Breast cancer xenografts
MDA-MB-468 control (siGFP) or triple siRNA (siBUB1, siPLK1 and
siCCNA2) transfected cells were trypsinized, counted and subcuta-
neously injected into the lower back of 4-week-old SCID mice (Charles
River Laboratories, Lecco, Italy) using 10106 cells in 100ml DMEM
with 30% matrigel (BD Biosciences, San Jose, CA, USA) per injection.
Once cancer cells have developed palpable tumours, caliper measure-
ments were taken and tumour volume was calculated using the
formula {V¼ [length (width)2]/2} (by manual caliper). For miR-10b
injection experiment, 50ml synthetic miRNA (Austin, TX, USA; pre-miR,
cat. no. AM17100) complexed with the siPORTamine transfection
reagent (Ambion, Austin) was delivered intratumourally in 3-day
intervals, when tumours reached an average volume of 100mm3. For
each injection, 6.25mg miRNA was complexed with 1.6ml siPORTa-
mine (Ambion; cat. no. AM4502) reagent in 50ml PBS. At the end of
the treatments animals were sacrificed in accordance with standard
protocols, tumours were collected and prepared for histology and RNA
isolation. All the procedures involving animals and their care were
approved by the Ethical Committee of Italian National Cancer
Institute ‘Regina Elena’ and conformed to the relevant regulatory
standards in accordance with Italian legislation.
For more detailed Materials and Methods see the Supporting
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